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The linoleic acid isomerase enzyme from Propionibacterium acnes responsible for bioconversion
of linoleic acid to trans-10, cis-12 conjugated linoleic acid (t10, c12 CLA) was cloned and
overexpressed in Lactococcus lactis and Escherichia coli, resulting in between 30 and 50%
conversion rates of the substrate linoleic acid to t10, c12 CLA. The anti-proliferative activities
of the fatty acids produced following isomerization of linoleic acid by L. lactis and E. coli were
assessed using the human SW480 colon cancer cell line. Fatty acids generated from both
L. lactis and E. coli contained a mixture of linoleic acid and t10, c12 CLA at a ratio of ~1.35:1.
Following 5 days of incubation of SW480 cells with 5–20 mgm l
”1 (17.8–71.3 mM) of the t10,
c12 CLA, there was a significant (P,0.001) reduction in growth of the SW480 cancer cells
compared with the linoleic acid control. Cell viability after treatment with the highest concentration
(20 mgm l
”1) of the t10, c12 CLA was reduced to 7.9% (L. lactis CLA) and 19.6% (E. coli CLA),
compared with 95.4% (control linoleic acid) and 31.7% (pure t10, c12 CLA). In conclusion,
this is believed to represent the first report in which recombinant strains are capable of producing
CLA with an anti-proliferative potential.
INTRODUCTION
Conjugated linoleic acids (CLAs) are a family of positional
and geometric isomers of linoleic acid with conjugated
double bonds. Biological activities associated with the cis-9,
trans-11 CLA (c9, t11 CLA) and the trans-10, cis-12 CLA
(t10, c12 CLA) isomers include anti-cancer, anti-athero-
sclerotic, anti-diabetic and immune-enhancing properties,
and positive effects on body composition and bone for-
mation (Belury, 2002; Pariza et al., 1999, 2000). A number
of studies have shown that the t10, c12 CLA isomer is the
most potent isomer for prevention of cell proliferation and
induction of apoptosis in cancer cells (Cho et al., 2005,
2006; Lee et al., 2006; Kim et al., 2002a; Ochoa et al., 2004).
Furthermore, this isomer has the ability to alter body
composition by reducing the fat content and increasing the
lean body tissue in animal models, and also in some studies
with humans (Smedman & Vessby, 2001; Blankson et al.,
2000; Thom et al., 2001).
c9, t11 CLA is formed as an intermediate during bio-
hydrogenation of linoleic acid by rumen bacteria, and
consequently natural sources of this isomer are milk and
fats from ruminants. The main CLA isomer in milk fat is
c9, t11 CLA, which accounts for 80–90% of total milk fat
CLA, whereas the t10, c12 CLA isomer is only present at
about 1% (Jensen, 2002). A range of cultures with the
ability to convert linoleic acid to c9, t11 CLA are known, in
addition to the rumen microflora. We have previously
shown that some human-derived Bifidobacterium species
can produce CLA (Coakley et al., 2003; Rosberg-Cody et al.,
2004). The predominant isomer formed after 48–72 h
incubation with 0.5 mg linoleic acid ml
21 is c9, t11 CLA,
with some of this isomer further converted to the t9, t11
CLA isomer (Coakley et al., 2006). Other species reported
to biosynthesize CLA, mainly the c9, t11 CLA isomer, are
propionibacteria used as dairy starter cultures (Jiang et al.,
1998), strains of the intestinal flora of rats (Chin et al.,
1994), Lactobacillus (Lin et al., 1999), Corynebacterium
(Fairbank et al., 1988, 1989), Lactococcus (Kim & Liu, 2002)
and some common bacterial lung pathogens (Jack et al.,
1994). The only known species which can perform a c9t o
t10 isomerization are Propionibacterium acnes isolated from
Abbreviations: CLA, conjugated linoleic acid; c9, t11 CLA, cis-9, trans-
11 CLA; t10, c12 CLA, trans-10, cis-12 conjugated linoleic acid; PAI, P.
acnes isomerase.
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bacterium Megasphaera elsdenii (Kim et al. 2000, 2002b). P.
acnes has been shown to convert ~85% of linoleic acid into
t10, c12 CLA after 24 h of incubation and ~10% into t10
octadecenoic acid (Verhulst et al., 1987). Since both
reaction products have proved to be derived from linoleic
acid, the results indicate that the c9 double bond of linoleic
acid is first isomerized into a t10 double bond, partly
followed by reduction of the c12 double bond (Verhulst
et al., 1987). The t10, c12 CLA could be formed from
linoleic acid alone by P. acnes and M. elsdenii, and not from
linolenic acid, as with the c9, t11 CLA isomer (Verhulst
et al., 1987; Kim et al., 2000).
The mechanisms by which CLA exerts all its physiological
effects are not yet fully understood, but at least two differ-
ent pathways have been proposed. The first suggests that
CLA reduces the arachidonate pool, leading to a reduced
production of downstream eicosanoid products, which
modulates cytokine production involved in inflammation
and cancer. The other model includes the regulation of
expression of genes known to control the cell cycle and
apoptosis, but also lipid oxidation, adipocyte differentia-
tion, energy balance and atherogenesis (Belury, 2002; Pariza
et al., 2000). Recently, it has been proposed that different
CLA isomers produce different effects. The t10, c12 CLA
isomer seems to work preferentially through modulation of
apoptosis and cell cycle control, while c9, t11 CLA appears
to affect arachidonic acid metabolism. The t10, c12 CLA
isomer has been shown to control the cell cycle and induce
apoptosis by decreasing bcl-2 gene expression and increas-
ing p21
WAF1/Cip1 mRNA levels in prostate cancer cells
(Ochoa et al., 2004). It has been shown to activate caspase-3,
and -9, translocate the anti-apoptotic protein Bax into the
mitochondrial membrane and cleave the anti-apoptotic
protein Bid in rat hepatoma cells (Yamasaki et al., 2005),
along with induction of caspase-dependent apoptosis in
MIP-101 and PC-3 cells (Palombo et al., 2002). This isomer
has also been reported to decrease cell growth due to a
decrease in the secretion of insulin-like growth factor II
(IGF-II) in Caco-2 colon cancer cells (Kim et al., 2002a), and
to cause a decrease of expression of the oncogene ErbB3 in
HT-29 human colon cancer cells (Cho et al.,2 0 0 5 ) .L e eet al.
(2006) have reported that t10, c12 CLA induces pro-
apoptotic and anti-tumorigenic NAG-1 in human colorectal
cancer cells. Moreover, t10, c12 CLA induces p53, p21 and
p27, and reduces the levels of cyclins D1 and E and hyper-
phosphorylated retinoblastoma protein (required for G1 to S
phase transition) in human breast cancer cells (Kemp et al.,
2003). Cho et al. (2006) have reported the induction by t10,
c12 CLA of G1 cell cycle arrest through increased expression
of p21, as well as decreased CDK2 activity, decreased levels
of hyperphosphorylated retinoblastoma (Rb) protein and
increased hypophosphorylated Rb protein in HT-29 colon
cancercells.However, anintegrated modelof the mechanism
of action of t10, c12 CLA has not been developed to date.
The aims of this study were to clone and overexpress the
linoleic acid isomerase capable of producing t10, c12 CLA
from P. acnes (Hornung et al., 2005) in Lactococcus lactis
and Escherichia coli, and to investigate the anti-proliferative
activity of the generated t10, c12 CLA using the human
SW480 colon cancer cell line.
METHODS
Cultures and media. L. lactis NZ9800 (an L. lactis NZ9700 derivative
which, due to a deletion in the nisA gene, does not produce nisin, and
which contains the nisRK signal transduction genes integrated on the
chromosome) was cultured at 30 uC in M17 (Difco) broth and/or
agar containing glucose (0.5%, w/v). L. lactis carrying the plasmid
pNZ44 was routinely cultured in the presence of chloramphenicol
(5 mgm l
21) as a selective marker. E. coli DH5a (TOP 10, Invitrogen)
harbouring the plasmid pNZ44 was cultured in Luria–Bertani (LB)
media supplemented with chloramphenicol (20 mgm l
21) with
shaking at 37 uC.
Human colon cancer cells were obtained from the American Type
Culture Collection (ATCC). The SW480 cell line was originally estab-
lished from a primary adenocarcinoma of the colon (Leibovitz et al.,
1976). The cell line is somewhat dedifferentiated, lacking many of the
phenotypic markers of normal colon epithelial cells. SW480 cells do
retain an epithelial-like morphology, with regular polygonal cells
predominating in culture, with some round cells. The t10, c12 CLA
isomer (.98% purity) was obtained from Matreya and linoleic acid
was purchased from Sigma Aldrich. Cell culture media and supple-
ments were purchased from Sigma, unless otherwise stated. SW480
cells were maintained in Dulbecco’s Minimum Essential Medium
(DMEM) supplemented with 5% (v/v) fetal bovine serum, 0.2 mM
L-glutamine, 1 mM HEPES, and 1 U ml
21 penicillin and streptomy-
cin. SW480 cells were grown in 75 ml flasks and maintained at 37 uC
in a humidified atmosphere at pH 7.2–7.4 with a flow of 95% air/5%
CO2, as required.
DNA manipulation. Two oligonucleotide primers were designed to
amplify the complete linoleic acid isomerase (coPAI) for production
of t10, c12 CLA from the original construct pC33.1-coPAI (linoleic
acid isomerase gene in a plant vector; BASF). The forward primer,
designated ERcoPAI1, contained a PstI restriction site and a ribosome-
binding site (RBS), four extra bases at the 59 end and seven extra bases
between the RBS and the gene start: 59-AAAACTGCAGAGGAGGAAAAAAA-
ATGGGTTCCATTTCCAAGGA-39, where bold capitals represent
part of the DNA sequence and small capitals represent artificial
sequence (e.g. restriction sites and added bases). The reverse primer,
designated ERcoPAI2, contained a KpnI restriction site and three
extra bases at the 59 end: 59-CGGGGTACCTCACACGAAGAACCGCG-
TCA-39. The 1278 bp coPAI gene was amplified in an Eppendorf
Mastercycler Gradient with High Fidelity Expand polymerase, as de-
scribed by the supplier (Roche Diagnostics) using 200 ng plasmid
DNA (pC33.1-coPAI) as template. PCR reactions were performed in a
total volume of 50 ml containing 1 ml of each primer, 3 mM MgCl2,
5 ml1 0 6 Expand buffer, 1 ml dNTPs and 0.75 ml Expand polymerase.
PCR conditions were as follows: one cycle of 2 min denaturation
(94 uC), 10 cycles of 15 s denaturation (94 uC), 30 s annealing
(55 uC), 2 min elongation (72 uC), followed by 20 cycles of 15 s
(94 uC), 30 s (55 uC), 2 min+5 s per cycle (72 uC), and finally one 7
min cycle at 72 uC. The PCR reaction mixture was analysed in a 1%
(w/v) agarose gel to visualize the resulting PCR fragment.
The Qiagen Plasmid Mini kit was used to isolate plasmid DNA from
E. coli and L. lactis NZ9800, with one minor modification for L. lactis,
i.e. 40 mg lysozyme ml
21 was added to buffer P1 and incubated for
20 min at 37 uC. PCR products were purified using a Qiaquick
PCR Purification kit (Qiagen). The two plasmids pNZ8048 (nisin-
inducible plasmid containing PnisA promoter, initially used for
E. Rosberg-Cody and others
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which the PnisA promoter is replaced by P44, a constitutive L. lactis
chromosomal promoter), and the coPAI gene fragment, were
restricted with PstI and KpnI, followed by a ligation reaction at
15 uC with T4 DNA ligase, as described by the supplier (New England
Biolabs), resulting in the construct pEV01, shown in Fig. 1. Recom-
binant plasmids were double-digested with the same enzymes to
verify the correct clone and then electroporated into L. lactis NZ9800.
Electrocompetent L. lactis was prepared and transformed according
to the method described by de Ruyter et al. (1996). Chemically
competent E. coli DH5a (TOP 10) was purchased from Invitrogen.
The authenticity of the clones was verified by sequencing (MWG-
Biotech) and sequence analysis was performed using DNASTAR
software.
Screening for CLA production. The L. lactis pEV01 and E. coli
pEV01 clones were tested for their ability to convert free linoleic acid
(0.1–0.5 mg ml
21)t ot10, c12 CLA as follows. Inoculum (1%) of an
overnight culture was transferred to 10 ml of the appropriate broth
and incubated until the culture reached OD600 ~0.5. Then, linoleic
acid (0.1–0.5 mg ml
21) (added from a 30 mg ml
21 stock solution,
sterile-filtered through a 0.45 mm filter, Sarstedt) was added to
cultures, followed by further incubation to 72 h. Following
incubation, the culture was centrifuged (4345 g) for 20 min and
fatty acids were extracted from the supernatant and cell pellets,
followed by methylation and analysis by GLC, as described by Coakley
et al. (2003). All conversion rates (%) were related to the amount of
linoleic acid that was recovered and extracted from the media
following incubation without culture for the same time as with
culture, which represents 100% of available linoleic acid. All
experiments were done at least in triplicate.
Preparation of fatty acids. The E. coli and L. lactis pEV01 clones,
as well as L. lactis and E .coli vector controls (empty pNZ44) were
inoculated (1% overnight culture) into 500 ml of the respective
media and grown to OD600 ~0.5, after which linoleic acid (0.5 mg
ml
21) was added and incubation continued to 72 h. A linoleic acid
control consisting of medium containing linoleic acid (0.5 mg ml
21)
but without culture was also prepared and incubated at 37 uC for
72 h. After 72 h, fatty acids (fermented oils) were co-extracted from
the supernatant and the bacterial pellet, as described for the super-
natant (Coakley et al., 2003), but with the difference that the super-
natant was not separated from the growing culture by centrifugation
prior to fatty acid extraction. Control samples from fermentations
were also prepared, methylated and analysed by GLC in triplicate to
calculate the amounts of fatty acids and the CLA:linoleic acid ratio
for the samples.
Anti-proliferative activity of fatty acids on human SW480 colon
cancer cells. To examine the anti-proliferative activity of the fatty
acids extracted following fermentation of cultures of L. lactis and
E. coli pEV01 in the respective media containing linoleic acid (0.5 mg
ml
21), SW480 human colon cancer cells were cultured in the presence
of different concentrations of the extracted fatty acids. The fermented
oils generated from both L. lactis and E. coli (pEV01) expressing
coPAI contained a mixture of linoleic acid and t10, c12 CLA at a ratio
of ~1.35:1. All samples, except for the pure t10, c12 CLA standard,
contained smaller amounts of palmitic, stearic and oleic acids. E. coli
fermented oil also contained 1.6% t9, t11 CLA (Table 1). Since the
recombinantly produced t10, c12 CLA samples contained even more
linoleic acid as well as other fatty acids, all calculated concentrations
added to the SW480 cancer cells were based on the amount of t10, c12
CLA present in the samples (or linoleic acid in the control sample,
and the fermented oil samples from the L. lactis and E. coli vector
controls). Initially, 1610
4 cells were seeded per well in 96-well plates
and cultured for 24 h at 37 uC to allow the cells to adhere to the
surface prior to treatment with 5–20 mg (ml medium)
21 t10, c12 CLA
(bacterial t10, c12 CLA/linoleic acid mix and pure Matreya standard
in ethanol) and 5–25 mg (ml medium)
21 linoleic acid (control fatty
acid extracted from broth). All fatty acids were sterile-filtered through
a 0.2 mm Millex FG filter unit (Millipore) for non-aqueous solvents.
Control flasks were supplemented with ethanol to a final concentration
of 0.1% (v/v). Following incubation for 5 days, cell viability was
measured and relative cell numbers were determined using the MTS
method (Promega), a colorimetric method for determining the
number of viable cells in proliferation or cytotoxicity assays,
subsequent to incubation with MTS tetrazolium compound.
Following incubation with MTS for 2 h, A492 was recorded with a
96-well plate reader. Cell viability (%) after treatment was expressed
relative to the ethanol control(100%). Three independent experiments
were performed on separate occasions, each time in triplicate for each
fatty acid/fermented oil treatment of SW480. Student’s t test was used
to determine significant differences between treatments (P,0.001).
RESULTS
Sequence analysis
The 1278 bp gene from P. acnes (Hornung et al., 2005)
encodes a linoleic acid isomerase protein of 425 aa. The
molecular mass of the isomerase is 49077 Da. Comparison
with sequences in the database revealed that the cloned
isomerase protein showed significant homology with flavin-
containing amino oxidases over most of the sequence
(approx. amino acids 25–400; NCBI Conserved Domain
Database; http://www.ncbi.nlm.nih.gov/Structure/cdd/cdd.
shtml). The isomerase showed 96% identity to a putative
amino oxidase from P. acnes (GenBank accession no.
Q6A8X5_PROAC; EXPASY/UniProtKB database), but
only 26% identity to the next best match, a protein from
the plant Oryza sativa (japonica cultivar group; accession
Fig. 1. The pEV01 construct (above) and a representative GLC
chromatogram (below) of supernatant following 72 h incubation of
L. lactis pEV01 in media containing 0.5 mg linoleic acid ml
”1.
Peaks: 1, C16:0 (palmitic acid); 2, C18:0 (stearic acid);
3, C18:1 (oleic acid); 4, C18:2 (linoleic acid); 5, C18:2 (t10,
c12 CLA).
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(http://www.expasy.ch/cgi-bin/blast.pl) spanning amino
acids 145–423. The aligned region in these proteins
includes a flavin binding site. The flavin-containing amine
oxidase family also contains phytoene hydrogenases and
related enzymes. An NAD/FAD binding domain located in
the region between amino acid residues 10 and 39 was
identified by the Prosite database (http://www.expasy.org/
prosite/). The crystal structure of the isomerase protein
PAI (P. acnes isomerase) has recently been determined
(Liavonchanka et al., 2006), which has confirmed the
protein to be an FAD-containing monomer consisting of
three intricately connected domains. Structural compar-
isons also show that the closest homologues of the iso-
merase protein domain 1, identified by the DALI program
(www.ebi.ac.uk/dali) are FAD-containing oxidoreductases
and isomerases, such as yeast polyamine oxidases. No
structural homologues of PAI domains 2 and 3 have been
found (DALI database) (Liavonchanka et al., 2006). The
isomerase protein is soluble (http://www.psort.org/psortb/)
and the predicted location of the protein is cytoplasmic
(http://bp.nuap.nagoya-u.ac.jp/sosui/sosuimenu0E.html).
Bioconversion of linoleic acid
L. lactis carrying the construct pEV01 was shown to con-
vert free linoleic acid into t10, c12 CLA, while the control
L. lactis culture containing the vector pNZ44 alone pro-
duced no CLA isomers. L. lactis pEV01 converted .50%
of the free linoleic acid to t10, c12 CLA (Figs 1 and 2).
Interestingly, L. lactis pEV01 accumulated a large amount
of t10, c12 CLA in the cell pellets. After 72 h incubation, up
to 60% of total t10, c12 CLA was recovered in the bacterial
membranes. Nearly all the t10, c12 CLA that was recovered
in the membranes was already incorporated after half the
incubation time (36 h). At this time point, the concentra-
tion of t10, c12 CLA in the supernatant was only about half
of the final concentration (Fig. 2). Given that L. lactis did
not grow well when initially incubated in the presence of
linoleic acid (0.4–0.5 mg ml
21), the fatty acid was instead
added to the growing culture at OD600 0.5. At this growth
stage, the culture still showed sensitivity to linoleic acid,
resulting in a reduced growth rate at this linoleic acid
concentration. Greater rates of conversion to t10, c12 CLA
were observed at lower concentrations of free linoleic acid
(0.1 and 0.2 mg ml
21). E. coli cells carrying the construct
pEV01 converted about 40% of linoleic acid after 72 h
incubation in the presence of the fatty acid (0.5 mg ml
21),
whereas E. coli pNZ44 (vector control) did not produce
any CLA. Compared with L. lactis pEV01, E. coli pEV01
accumulated much less CLA in the membranes: only about
10% of total t10, c12 CLA.
Anti-proliferative activity of microbially generated
fatty acids on human SW480 colon cancer cells
To investigate the anti-proliferative effects of fatty acids
produced following isomerization of linoleic acid by L.
lactis pEV01 and E. coli pEV01, human colon cancer cells
(SW480) were cultured in the presence of the extracted
fermented oils (consisting of a mixture of linoleic acid and
Table 1. Fatty acid composition of the various fatty acid treatments (% of total fatty acids in samples)
Values represent the mean of triplicate analyses±SD.
Fatty acid treatment Fatty acid composition (percentage of total fatty acids)
C16:0 C18:0 C18:1
c9
C18:2
c9, c12
C18:2 t10,
c12 CLA
C18:2 t9,
t11 CLA
Control linoleic acid 0.7±0.06 1.2±0.15 5.4±0.06 92.7±0.2 22
Pure t10, c12 CLA 222 2100 2
E. coli (pEV01) fermented oils 4.2±0.0 1.6±0.07 6.2±0.0 49.2±0.07 37.3±0.28 1.6±0.42
L. lactis (pEV01) fermented oils 1.1±0.06 1.8±1.5 4.3±3.29 53.7±1.8 39.0±1.5 2
E. coli (pNZ44) vector control fermented oils 4.0±0.28 1.2±0.07 4.8±0.14 90.1±0.49 22
L. lactis (pNZ44) vector control fermented oils 0.8±0.07 0.9±0.07 4.9±0.07 93.3±0.07 22
Fig. 2. t10, c12 CLA production versus linoleic acid usage and
accumulation of the fatty acids in the cell pellets by L. lactis pEV01
incubated with 0.2 mg linoleic acid ml
”1 for 72 h. The culture was
incubated in linoleic acid at OD600 0.5. Samples were analysed in
triplicate. &, t10, c12 CLA supernatant; ., linoleic acid super-
natant; m, t10, c12 CLA bacterial pellets; X, linoleic acid bacterial
pellets.
E. Rosberg-Cody and others
2486 Microbiology 153t10, c12 CLA at a ratio of ~1.35:1, and smaller amounts of
other fatty acids; Table 1). Controls of linoleic acid
extracted from LB broth after 72 h incubation at 37 uC
and of the pure synthetic t10, c12 CLA standard, but also
controls of fermented oils from L. lactis and E. coli
transformed with the empty vector, were inoculated with
SW480 cells. Since linoleic acid has been shown to have an
anti-proliferative effect on SW480 cancer cells at higher
concentrations [42.8 mg (ml medium)
21; 152.5 mM], and a
slightly proliferative effect at a lower concentration [16.9 mg
(ml medium)
21; 60.2 mM] (Miller et al., 2003), concentra-
tions of t10, c12 CLA (microbially generated fatty acid
samples) between 5 and 20 mg (ml medium)
21 [equivalent
to 6.7–27 mg linoleic acid (ml medium)
21 in the same fatty
acid sample] were chosen so as not to exceed the threshold
concentration at which linoleic acid inhibits cell growth.
Therefore, the highest linoleic acid concentration added to
the cancer cells was 25 mg (ml medium)
21 from the control
samples, to examine the effect of linoleic acid alone, given
that the fermented oil samples contained approximately
this concentration of linoleic acid together with 20 mg (ml
medium)
21 t10, c12 CLA. Following 5 days of incubation
with t10, c12 CLA between 5 and 20 mgm l
21, there was a
significant (P,0.001) reduction in growth of the SW480
cancer cells compared with control linoleic acid at all
concentrations. Average cell viability following treatment
with the highest concentration (20 mgm l
21)o ft10, c12
CLA was reduced to 7.9% (L. lactis fermented oil) and
19.6% (E. coli fermented oil), compared with 95.4%
(control linoleic acid+L. lactis vector control fermented
oils) and 95.6% (E. coli vector control fermented oils)
(Fig. 3). Viable cell numbers following treatment with the
highest concentration (25 mgm l
21) of linoleic acid were
decreased to 76%, which showed that this concentration
had a slight anti-proliferative effect on the SW480 cells and
therefore must have contributed to the killing effect of the
highest concentrations of the fermented oils. All figures are
related to ethanol controls (100% cell viability). Significant
differences in cell viability were observed at all concentra-
tions between the control linoleic acid and the t10, c12 CLA
from L. lactis and E. coli (P,0.001). There was no signifi-
cant difference in cell viability after treatment between E.
coli t10, c12 CLA and the pure t10, c12 CLA standard at any
concentration. However, there was a significant difference
in cell viability between treatments with L. lactis t10, c12
CLA and the pure t10, c12 CLA standard at concentrations
between 10 and 20 mgm l
21 (P,0.001) (Fig. 3).
DISCUSSION
We have successfully cloned and overexpressed the t10, c12
CLA isomerase from P. acnes in L. lactis and E. coli. The
recombinant isomerase protein was functionally active,
with conversion rates of .50% of the added linoleic acid
to t10, c12 CLA when expressed in L. lactis, and 40% in
E. coli. The isomerase protein was also expressed in the
probiotic strain Lactobacillus paracasei subsp. paracasei
NFBC 338, which was also capable of converting linoleic
acid to t10, c12 CLA (data not shown). The enzyme has
previously been characterized and expressed in bacteria,
yeast and tobacco seeds (Rosson et al., 2001; Hornung et al.,
2005). However, not many sequences of polyunsaturated
fatty acid isomerases are known, and the homology
between coPAI and other fatty acid isomerase sequences
in the database was not significant. Recently, Liavonchanka
et al. (2006) have described six crystal structures of PAI,
which has revealed a unique gating mechanism for
substrate specificity due to conformational changes in a
hydrophobic channel toward the active site. The length
preference for C18 fatty acids can thus be explained by the
geometry of the substrate binding site.
Interestingly, higher conversion rates of linoleic acid to t10,
c12 CLA were achieved with recombinant lactococci than
with recombinant E. coli, while the former were more
sensitive to free linoleic acid. For this reason, the linoleic
Fig. 3. Cell viability of SW480 cells after 5 days of incubation with
5–20 mg (ml medium)
”1 t10, c12 CLA (fermented oils from CLA-
producing L. lactis and E. coli or pure t10, c12 CLA) or 5–25 mg
(ml medium)
”1 linoleic acid (control linoleic acid extracted from
broth and fermented oils of L. lactis and E. coli vector controls).
Data represent cell viability expressed as a percentage of the
ethanol control, which was taken as 100%. White bars, control
linoleic acid (extracted from broth after 72 h incubation); light-grey
bars, E. coli pEV01 fermented oil; dark-grey bars, pure t10, c12
CLA standard (Matreya); black bars, L. lactis pEV01 fermented oil;
diagonal-hatched bars, L. lactis vector control fermented oil;
horizontal-hatched bars, E. coli vector control fermented oil. Since
the recombinantly produced t10, c12 CLA samples also contained
other fatty acids, all calculated concentrations were based on the
amount of t10, c12 CLA (or linoleic acid in the control samples)
present in the samples. Three independent experiments were
performed on separate occasions and each time in triplicate for
each fatty acid treatment, and Student’s t test was used to
determine significant differences between treatments. Error bars
represent SD. ***Values significantly different (P,0.001) from that
of the control (linoleic acid extracted from broth).
Expression of microbial linoleic acid isomerase
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reached OD600 ~0.5. Another notable feature of L. lactis
CLA production was that approximately half of the pro-
duced t10, c12 CLA was cell associated and could be
extracted from pelleted cells. The reason for this is
unknown, but could be related to the fact that poly-
unsaturated fatty acids are antibacterial (Kankaanpa ¨a ¨ et al.,
2001), and the demonstrated incorporation into the mem-
branes might be part of a detoxification mechanism (Jiang
et al., 1998) used by L. lactis. A positive correlation between
the inhibitory activity of a fatty acid and the level to which
the fatty acid is incorporated into the cell membrane has
been reported (Khulusi et al., 1995). In general, a long-
chain fatty acid with a higher degree of unsaturation is
more inhibitory than a fatty acid of the same chain length
with fewer double bonds. Also, Gram-negative bacteria
are less susceptible than Gram-positive bacteria to long-
chain unsaturated fatty acids (Jenkins & Courtney, 2003).
In particular, linoleic acid is known to exhibit an inhibi-
tory effect towards some bacteria, e.g. Lactobacillus
(Alonso et al., 2003) and propionic acid bacteria (Jiang
et al., 1998).
The anti-proliferative effect of the fatty acids produced by
L. lactis and E. coli on human SW480 cancer cells was
confirmed in this study. Cell growth inhibition by t10, c12
CLA was dose-dependent, with the highest growth inhibi-
tory effect at concentrations of 20 mgm l
21 t10, c12 CLA.
Most effective was L. lactis fermented oil, which left only
8% viable cells (compared with the ethanol control). E. coli
fermented oil caused a reduction of viable cell numbers
to 20%. Linoleic acid alone also showed a slight anti-
proliferative effect on the cancer cells following incubation
with media containing 25 mgm l
21, and therefore must
have contributed to the killing effect of the highest con-
centrations of the fermented oils.
Microscopic examination of the SW480 colon cancer cells
following 5 days of incubation with the various fatty acids
treatments (Fig. 4) confirmed the results from the MTS cell
viability assay (Fig. 3). SW480 cells incubated with 20 mg
linoleic acid ml
21 were largely unaffected, in terms of
either cell numbers or morphology (Fig. 4a, b). In contrast,
in the samples incubated with 20 mgm l
21 L. lactis and
E. coli (pEV01) fermented oils, there was a noticeable
reduction in cell numbers presenting a viable epithelial-like
morphology. Cells undergoing cell death and associated
morphological changes were also evident (Fig. 4c–f).
An interesting observation was the increased inhibition
of SW480 cell numbers in the samples treated with the
L. lactis (pEV01)-generated fermented oil, compared with
the samples treated with the same concentration of pure
CLA standard or E. coli (pEV01) fermented oil. The added
anti-proliferative effect of lactococcal-derived oil compared
with that from E. coli may be due to other hydrophobic
constituents which were co-extracted with the fatty acids.
These putative constituents do not appear to have anti-
proliferative activity on their own, given that the vector
controls did not exhibit significant anti-proliferative
activity. It is possible that such hydrophobic constituents
act synergistically with the t10, c12 CLA isomer to give the
observed increased killing with L. lactis-derived oils.
The t10, c12 CLA isomer has been shown to inhibit growth
and induce apoptosis in a number of cell lines, such as
HT-29 human colon cancer cells (Cho et al., 2005, 2006),
Caco-2 colon cancer cells (Kim et al., 2002b), human
colorectal cancer (CRC) cells (Lee et al., 2006), dRLh-84 rat
hepatoma cells (Yamasaki et al., 2005) and the PC-3
human prostatic carcinoma cell line (Ochoa et al., 2004),
while similar effects have not been reported for the c9, t11
CLA isomer at the same concentrations.
Both c9, t11 CLA and t10, c12 CLA have been shown to
inhibit growth of MCF-7 cells (Scultz et al., 1992; O’Shea
et al., 1999). The human SW480 colon cancer cell line was
chosen in the present study, as it has previously been
shown to be efficient as an in vitro cancer model (Miller
et al., 2001, 2002, 2003). In the study of Miller et al. (2002),
the t10, c12 CLA isomer was the most potent isomer
examined, reducing cell viability by 47–61% at a con-
centration of 16 mgm l
21, compared with a 40–52%
Fig. 4. Micrographs of human SW480 colon cancer cells
following 5 days of incubation with the different fatty acid
treatments. (a, b) Linoleic acid control (extracted from broth); (a)
5 and (b) 20 mg (ml medium)
”1. (c, d) E. coli (pEV01) fermented
oils containing (c) 5 and (d) 20 mg (ml medium)
”1 t10, c12 CLA.
(e, f) L. lactis (pEV01) fermented oils containing (e) 5 and (f) 20 mg
(ml medium)
”1 t10, c12 CLA. All panels are 100 magnification;
bar, ** mm.
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same concentration of t10, c12 CLA reduces viability by
50–60% in both SW480 and the MCF-7 breast cancer cell
line following 4 days of incubation (Miller et al., 2001). In
contrast, 16 mg linoleic acid ml
21 increases viability of
SW480 cells by 23% (Miller et al., 2001). Linoleic acid,
however, has also been shown to inhibit growth of SW480
cells at higher concentrations. Incubation with 42.8 mg
ml
21 (152.5 mM) linoleic acid reduces viability by 40%
after 3 days of incubation (Miller et al., 2003).
In order to be a valuable therapeutic agent for cancer, CLA
or any other anti-proliferative agent must demonstrate
selective growth inhibition of cancer cells. A number of
studies have presented evidence supporting such a claim
for CLA for a range of tissue types. No cytotoxic or apopto-
tic effect of CLA (as a blend of isomers and specific
isomers) has been found on human osteoblast-like cells
(SaOS2 and MG63) in culture at a concentration range of
0–50 mM (Cusack et al., 2005). Similarly, neither apoptosis
nor any of the apoptosis regulatory proteins was affected by
CLA in normal mammary gland alveoli or terminal end
buds, whereas CLA inhibited the formation of pre-
malignant lesions of rat mammary gland by ~50% and
significantly increased apoptosis, reducing the expression
of bcl-2 in these lesions (Ip et al., 2000). Yamasaki et al.
(2002) have demonstrated a decrease in viable cell numbers
of normal rat RLN-10 hepatocytes by the t10, c12 CLA
isomer only at 25 mM, compared with rat hepatoma dRLh-
84 cells, which are much more sensitive to t10, c12 CLA:
less than 25% viable cells persisted following treatment
with 1 mM of this isomer.
CONCLUSIONS
In this study, we have heterologously expressed linoleic
acid isomerase in L. lactis and E. coli, and in so doing
generated cultures which can produce t10, c12 CLA.
Moreover, this is believed to be the first instance in which
the CLA produced by recombinant strains has been shown
to exhibit an anti-proliferative effect. These results demon-
strate the potential for using recombinant strains to deliver
bioactive CLAs to (or produce within) the mammalian
intestine, where they exert an anti-proliferative activity.
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